BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 34,980 Shares of Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) CEO Neil Kumar sold 34,980 shares of the business’s stock in a transaction dated Wednesday, November 18th. The stock was sold at an average price of $77.72, for a total transaction of $2,718,645.60. Following the completion of the transaction, the chief executive officer directly owned 243,327 shares in the company, valued at $18,911,374.44. This trade represents a 12.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neil Kumar also recently made the following trade(s):

  • On Wednesday, November 18th, Neil Kumar sold 10,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $77.72, for a total transaction of $777,200.00.
  • On Thursday, September 17th, Neil Kumar sold 10,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $69.08, for a total transaction of $690,800.00.

BridgeBio Pharma Stock Down 2.8%

NASDAQ BBIO traded down $2.15 during trading hours on Friday, reaching $76.03. 1,478,712 shares of the company were exchanged, compared to its average volume of 2,889,236. BridgeBio Pharma, Inc. has a 1 year low of $62.50 and a 1 year high of $93.42. The business’s 50 day simple moving average is $70.22 and its 200-day simple moving average is $72.78. The stock has a market capitalization of $14.81 billion, a P/E ratio of -25.01 and a beta of 0.97.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.12. The company had revenue of $353.17 million during the quarter, compared to analysts’ expectations of $293.47 million. During the same quarter in the previous year, the firm earned ($0.95) earnings per share. The firm’s revenue was up 192.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that BridgeBio Pharma, Inc. will post -2.55 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the company. HC Wainwright reiterated a “buy” rating on shares of BridgeBio Pharma in a research note on Tuesday, October 6th. Wells Fargo & Company increased their price objective on BridgeBio Pharma from $98.00 to $102.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. raised their target price on BridgeBio Pharma from $100.00 to $111.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Truist Financial boosted their target price on BridgeBio Pharma from $102.00 to $107.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Citigroup dropped their price target on BridgeBio Pharma from $94.00 to $91.00 and set a “neutral” rating on the stock in a research report on Monday, October 19th. Nineteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $104.42.

Get Our Latest Report on BridgeBio Pharma

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Jupiter Topco LLC bought a new stake in BridgeBio Pharma during the 2nd quarter valued at $1,050,762,000. Janus Henderson Group PLC boosted its holdings in shares of BridgeBio Pharma by 19.8% in the first quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock worth $978,608,000 after acquiring an additional 2,178,556 shares during the period. The Manufacturers Life Insurance Company bought a new position in shares of BridgeBio Pharma in the second quarter worth $145,663,000. Primecap Management Co. CA purchased a new position in shares of BridgeBio Pharma in the second quarter valued at $75,670,000. Finally, Groupama Asset Managment purchased a new position in shares of BridgeBio Pharma in the third quarter valued at $720,000. 99.85% of the stock is owned by institutional investors.

About BridgeBio Pharma

(Get Free Report)

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.

Featured Articles

Insider Buying and Selling by Quarter for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.